Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.63)
# 195
Out of 5,124 analysts
141
Total ratings
51.61%
Success rate
42.5%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Buy | $9 | $2.01 | +347.76% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $25.01 | +67.93% | 2 | Dec 1, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $30 → $40 | $26.33 | +51.92% | 2 | Nov 21, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $12 | $8.96 | +33.93% | 1 | Nov 19, 2025 | |
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $6.72 | +138.10% | 20 | Nov 10, 2025 | |
| CYTK Cytokinetics | Reiterates: Buy | $80 → $90 | $63.54 | +41.64% | 5 | Nov 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $49.00 | +51.02% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $582.34 | -3.84% | 13 | Sep 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $85 → $105 | $42.28 | +148.34% | 3 | Sep 23, 2025 | |
| TGTX TG Therapeutics | Maintains: Buy | $53 → $55 | $29.81 | +84.50% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $18.71 | +49.65% | 1 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.12 | +226.80% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $3.61 | +398.61% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.31 | +281.68% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $1.61 | +86.34% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.35 | +479.54% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $12.52 | +59.74% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.67 | +79.64% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $16.51 | +111.99% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $66.39 | -42.76% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $35.18 | +172.88% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.35 | +11.11% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $12.20 | +1,047.54% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $4.00 | +2,150.00% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.14 | +4,995.54% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $3.22 | +55.28% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $1.98 | +2,122.22% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $3.66 | +2,359.02% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.56 | +348.72% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $0.98 | +458,615.60% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.16 | +232,658.62% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $6.13 | +1,156.12% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.75 | +191,772.09% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $4.16 | -3.85% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $98.51 | -60.41% | 2 | Mar 18, 2020 |
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $2.01
Upside: +347.76%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $25.01
Upside: +67.93%
Zymeworks
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $26.33
Upside: +51.92%
Nuvation Bio
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $8.96
Upside: +33.93%
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $6.72
Upside: +138.10%
Cytokinetics
Nov 10, 2025
Reiterates: Buy
Price Target: $80 → $90
Current: $63.54
Upside: +41.64%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $49.00
Upside: +51.02%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $582.34
Upside: -3.84%
Nektar Therapeutics
Sep 23, 2025
Maintains: Buy
Price Target: $85 → $105
Current: $42.28
Upside: +148.34%
TG Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $29.81
Upside: +84.50%
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $18.71
Upside: +49.65%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $6.12
Upside: +226.80%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $3.61
Upside: +398.61%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.31
Upside: +281.68%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.61
Upside: +86.34%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.35
Upside: +479.54%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $12.52
Upside: +59.74%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.67
Upside: +79.64%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $16.51
Upside: +111.99%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $66.39
Upside: -42.76%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $35.18
Upside: +172.88%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.35
Upside: +11.11%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $12.20
Upside: +1,047.54%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $4.00
Upside: +2,150.00%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.14
Upside: +4,995.54%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $3.22
Upside: +55.28%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $1.98
Upside: +2,122.22%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $3.66
Upside: +2,359.02%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.56
Upside: +348.72%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $0.98
Upside: +458,615.60%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.16
Upside: +232,658.62%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $6.13
Upside: +1,156.12%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.75
Upside: +191,772.09%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $4.16
Upside: -3.85%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $98.51
Upside: -60.41%